Skip to main content

Ductal Carcinoma In Situ

Anne Campbell Larkin, MD Reviewed 06/2022
 


BASICS

DESCRIPTION

  • Ductal carcinoma in situ (DCIS) is a heterogeneous group of lesions that have the presence of a clonal proliferation of neoplastic, noninvasive epithelial cells confined to ducts and...

DIAGNOSIS

HISTORY

  • Most DCIS is now diagnosed by screening mammography (presence of microcalcifications in approximately 72%); patients may be asymptomatic with nonpalpable mass (12%).

  • More advanced lesi...

TREATMENT

MEDICATION

  • Secondary chemoprevention following breast-conserving surgery for ER+ DCIS:

    • Tamoxifen for pre-menopausal patients or tamoxifen or an aromatase inhibitor for post-menopa...

ONGOING CARE

FOLLOW-UP RECOMMENDATIONS

  • History and physical exam should occur every 6 to 12 months for the first 5 years and then annually after that.

  • Mammography every 12 months (first mammogram 6 to 1...

REFERENCES

1
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer (Version 3.2018) 2018. http://www.nccn.org. Accessed November 8,...

ADDITIONAL READING

Siu  AL; for U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. ...

SEE ALSO

Breast Cancer 

CODES

ICD10

  • D05.10 Intraductal carcinoma in situ of unspecified breast

  • D05.11 Intraductal carcinoma in situ of right breast

  • D05.12 Intraductal carcinoma in situ of left breast

  • R92.0 Mammographic microcalc...

CLINICAL PEARLS

  • DCIS is a heterogeneous group of noninvasive neoplastic breast ductal epithelial cell lesions.

  • The incidence of DCIS has continued to increase in women <50 and >70 years of age, w...

Subscribe to Access Full Content

Sign Up for a 10-Day Free Trial

Sign up for a 10-day FREE Trial now and receive full access to all content.

 
×